ArticleOpen heart2025
Dual impact of anaemia and chronic kidney disease on postpercutaneous coronary intervention outcomes: insights from the Japanese nationwide registry.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Observation to Implementation: A Simple Pre-PCI Anemia Optimization Pathway.Cardiovascular drugs and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaemia and chronic kidney disease (CKD) are both established risk factors for bleeding events after percutaneous coronary intervention (PCI). These conditions often coexist; however, previous assessments of these factors individually may have led to an underestimation of their impact on clinical outcomes.
methodsWe analysed the data of 77 482 patients who underwent PCI between 2017 and 2020 in the Japanese nationwide PCI registry. Based on preprocedural anaemia (haemoglobin: <13 g/dL in men; <12 g/dL in women) and CKD (estimated glomerular filtration rate, <60 mL/min/1.73 m²) statuses, the patients were categorised into 'neither anaemia nor CKD' (n=36 629; 47.3%), 'CKD alone' (n=17 120; 22.1%), 'anaemia alone' (n=10 136; 13.1%) and 'both anaemia and CKD' (n=13 597; 17.5%) groups. The study endpoints included bleeding (fatal or non-fatal major bleeding) and ischaemic (cardiovascular death, non-fatal acute coronary syndrome or non-fatal ischaemic stroke) events.
resultsThe 1-year incidence of bleeding and ischaemic events was highest in the 'both anaemia and CKD' group and lowest in the 'neither anaemia nor CKD' group. After adjustment, 'anaemia alone' (HR 1.52; 95% CI 1.29 to 1.79; p<0.001) and 'both anaemia and CKD' (HR 1.39; 95% CI 1.18 to 1.63; p<0.001), but not 'CKD alone' (HR 1.00; 95% CI 0.85 to 1.17; p=0.97), were significantly associated with high risks of bleeding events compared with 'neither anaemia nor CKD'. All three groups had higher ischaemic risk compared with 'neither anaemia nor CKD' ('CKD alone': HR 1.29; 95% CI 1.16 to 1.45; p<0.001, 'anaemia alone': HR 1.40; 95% CI 1.22 to 1.60; p<0.001, 'both anaemia and CKD': HR 1.61; 95% CI 1.43 to 1.81; p<0.001).
conclusionsAnaemia increased bleeding risk regardless of CKD status, whereas 'CKD alone' did not. In addition, patients with anaemia and/or CKD were at a higher risk of ischaemic events. Clinicians should routinely perform initial risk assessments stratified by anaemia and CKD for patients undergoing PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.